In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Effect of trimetazidin, a metabolic modulator, in idiopathic dilated cardiomyopathy

Non-invasive Imaging: Nuclear Cardiology


 

Comment on the above paper

Trimetazidine is a metabolic modulator that may optimize myocardial energy metabolism and allow more efficient production of energy from glucose than from free fatty acids.  Trimetazidine has been studied extensively in heart failure predominantly of ischemic origin.  Tuunanen et al (1) have now used PET and echocardiographic imaging in a small group of patients with heart failure caused by nonischemic dilated cardiomyopathy.  They showed that trimetazidine 1) improves LV function in these patients, 2) reduced myocardial free fatty acid oxidation by only 10% in the failing human heart, raising the possibility of additional mechanisms of action, 3) has whole-body metabolic effects with increased sensitivity potentially linked to decreased whole-body  free fatty acid oxidation and  4) increases HDL levels by 11%.  Furthermore, the trimetazidine induced improvement in left ventricular function was linked to the degree of beta-blockade, suggesting an additive effect of these 2 therapies.  Further studies are of course warranted, but the authors have shown nicely how integrated imaging (in this case PET and echocardiography) may help to study the effects of metabolic modulators in patients with chronic heart failure.

References


  1. Tuunanen H, Engblom E, Naum A et al.  Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.  Circulation 2008;118:1250-1258.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.